Immunome (NASDAQ:IMNM – Get Rating) posted its earnings results on Thursday. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.27), Fidelity Earnings reports.
Shares of NASDAQ IMNM traded down $0.30 during trading hours on Friday, hitting $2.24. 35,558 shares of the stock were exchanged, compared to its average volume of 115,144. The company’s fifty day simple moving average is $4.38 and its two-hundred day simple moving average is $10.13. The company has a market cap of $27.17 million, a PE ratio of -0.82 and a beta of 0.03. Immunome has a 1-year low of $2.09 and a 1-year high of $27.80.
IMNM has been the subject of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunome in a research note on Monday, May 9th. Chardan Capital dropped their price objective on shares of Immunome from $16.00 to $9.00 in a research note on Friday. Finally, Zacks Investment Research upgraded shares of Immunome from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research note on Friday.
About Immunome (Get Rating)
Immunome, Inc, a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.
- Get a free copy of the StockNews.com research report on Immunome (IMNM)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.